Abstract:Abstract Background: Glioblastoma (GBM) is the most common malignant brain tumor in adults, with about 90% of tumors developing de novo. Their heterogeneity, aggressiveness and infiltrative growth limit success of current standard of care (SoC) therapy and efficacy of new therapeutic approaches. For drug development a large panel of patient-derived tumor cell models is needed to generate most comparable in vitro and in vivo platform reflecting the complex biology of glioblastoma. Glioblastoma cell lines from patient-derived xenografts (PDX) preserve many patient specific characteristics and to perform the essential steps of pre-clinical drug development from in vitro screening to orthotopic in vivo approaches under conditions, which closely resemble the clinical situation. Further, GBM PDX models are useful for immune oncology research. Methods: A panel of 26 glioblastoma PDX models was established on immunodeficient mice (15 out of these established orthotopically). All models were characterized for drug sensitivity and molecular profile using panel and transcriptome sequencing. From these, three corresponding tumor cell lines were successfully established and characterized. Quality and identity of the models was performed by FACS and PCR analysis. Expression profile, drug sensitivity and growth behavior was determined and compared in vitro and after re-transplantation in vivo with the original PDX glioma model. In addition, we employed GBM PDX models for checkpoint-inhibitor sensitivity in humanized mouse settings. Results: Drug testing was performed in s.c. and orthotopic models revealed, that best treatment responses in s.c. models (tumor growth inhibition > 50%) were observed for SoC temozolomide (TMZ), irinotecan and bevacizumab. Molecular characterization identified all our models as IDH-wt (R132) with frequent mutations in PARP1, EGFR, TP53, FAT1, and within the PI3K/AKT/mTOR pathway. Their expression profiles resemble proposed mesenchymal, proneural and classical GBM molecular subtypes. Further, treatment of GBM PDX with ipilimumab, nivolumab or pembrozolumab generated minor growth delay. Conclusions: In drug sensitivity screening, irinotecan or bevacizumab were identified as alternative treatment options in TMZ resistant GBM PDX models. Our data demonstrate, that the established platform of s.c. and orthotopic GBM PDX is valuable for drug development and can well be complemented by a PDX-derived cell lines for in vitro screens. Furthermore, these models can be used for the evaluation of new immune-oncology therapies. Citation Format: Joshua Alcaniz, Lars Winkler, Maria Stecklum, Hagen Wieland, Antje Siegert, Michael Becker, Bernadette Brzezicha, Wolfgang Walther, Jens Hoffmann. Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4674.

Tmod-31. Single-Cell Profiling And Characterization Of Patient-Derived Xenograft Glioblastoma Model In Humanized Mice

OS10.5.A Modeling immunocompetent tumor microenvironment in glioblastoma patient-derived orthotopic xenografts

Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice

Immu-66. Physiologically Relevant Murine Glioma Models That Represent Gbm Heterogeneity And Enable The Next Generation Of Discovery And Therapy Efficacy Studies

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

RBIO-03. HETEROGENEITY OF HUMAN PATIENT-DERIVED XENOGRAFTS GROWTH RATES RESPONSES TO THE RADIATED MICROENVIRONMENT

Translational Orthotopic Models of Glioblastoma Multiforme

Tmic-34. Infiltrative Behavior Of Patient-Derived Glioblastoma Cell Lines In Region-Specific Human Brain Organoids

A Xenotransplant Model of Human Brain Tumors in Wild-Type Mice

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment

Abstract 4674: Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research

Tmod-35. Egfrviii Overexpression And Loss Of Mouse Specific Cdkn2A In Glial Cells Leads To Spontaneous Gliomagenesis In A Novel Mouse Model

MODL-25. ANALYSIS OF TUMOR CELL HETEROGENEITY IN A HUMAN NEURAL PROGENITOR-BASED MODEL OF GLIOBLASTOMA REVEALS NEURODEVELOPMENTAL PROGRAMS AND CYTOSKELETAL DYNAMICS

Direct Implantation of Patient Brain Tumor Cells into Matching Locations in Mouse Brains for Patient-Derived Orthotopic Xenograft Model Development

Anatomically aware simulation of patient-specific glioblastoma xenografts

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses

Modeling Glioma Intratumoral Heterogeneity with Primary Human Neural Stem and Progenitor Cells

Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids

Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts

Abstract 1441: Establishing a novel clinically relevant disease model of glioblastoma